한국어
Quantus

KBIO LABS

038530 · KOSDAQ
₩4,125+312.91%
2026-09-21 close

KBIO LABS last closed at ₩4,125 (+312.91%) on 2026-09-21. Signals today: Bollinger breakout, MACD bullish cross. Listed on KOSDAQ; price, financials and dividends update daily after market close.

Loading chart…
Close
Market Leader RS 99 · top 1%

New high + volume — the real recordrecord · not a prediction

Last 30 sessions
191 picks
Next-day win rate
50.5%
Avg next-day
+0.01%
vs market
+0.05%p

Every new-high-plus-volume pick we actually published (Korea market) — not this stock alone.

Trade plan

Fill entry, stop, account size and risk percent to get a share count. The stop must sit below the entry.

A calculator · not advice or a guarantee

Financials & valuation at a glance

B+
Overall: 건강관리 100/304 · top 33%
Factor composite · relative position in sector

PER — · PBR 1.69 — own-history percentile 74/100 · 45/100

Open self-history band
PER74/100
PBR45/100

Factual information · not investment advice

Past reported results · not investment advice

More — deeper indicators

Financial safety

Reference indicatorAs of 2024
Safe zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 2.85
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
2.85
Beneish M-Score
-2.51

No statistical flag

Sloan accrual
-19.37%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

8/9Strong

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score8/9

Profitability

  • Positive ROANot passed
  • Positive OCFPass
  • Improving ΔROAPass
  • Accruals (OCF > net income)Pass

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioPass
  • No new sharesPass

Efficiency

  • Higher gross marginPass
  • Higher asset turnoverPass

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Margin trendWarning

영업이익률 악화 (40.1% → -3.8%, -43.9%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업외손익 급변 (영업이익 대비 678% 규모 변동) — 일회성 손익 주의. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Industry structure

KRAs of 2026-09-21

건강관리

This stock is in 건강관리: revenue rank 143 of 298, share 0.1%.

143 / 2980.1%revenue share

Who dominates this industry?

  1. 1삼성바이오로직스7.2%
  2. 2셀트리온5.7%
  3. 3녹십자홀딩스3.5%
  4. 4유한양행3.3%
  5. 5대웅3.1%
  6. 6케이바이오랩스0.1%

Concentration

DistributedCR3 16.4%
HHI 198298 revenue members

HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.

Polarization

Winner-take-all deepeningConsistent

Polarization measures industry gaps and structure, not valuation, forecast, or investment advice.

Margin lens

IQR%p
91.9
Direction
확대
Level
넓음
Years
7

Value lens

P90/P10
14
Median P/B
1.47
Level
넓음
n
271

Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-3.8%
Interest coverage
-37.3x
Return on equity (ROE)
-12.1%

Operating margin −5pp

Operating loss
Interest coverageBase -37.3x adverse case -86.4x
Return on equity (ROE)Base -12.1% adverse case -12.1%

Revenue −15%

Interest coverage risk
Interest coverageBase -37.3x adverse case -31.7x
Return on equity (ROE)Base -12.1% adverse case -4.5%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -37.3x adverse case -2.2x
Return on equity (ROE)Base -12.1% adverse case -7.5%

Interest coverage limit

Already below the limit by 3.9pp

Interest coverage limit at an operating margin of 0.1%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-03-23

Suppliers disclosed by the company in its 2026-03-23 annual report.

Purchase amount

KRW 100m
  1. 인콘Price comovement r=0.18 (1 year)
    KRW 516.2B

Suppliers without disclosed amount

ICT

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 미래아이앤지40.99%2026-09-04 · 증감 0.00%p

Other stocks held by the same investors

A filing-based shared-holder record, not investment advice.

Connections

AI-extracted related companies · for reference

Customers
PfizerNovartisRocheAmgen
🔗 See in the full market map →

Recent filings

KBIO LABS's latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

About KBIO LABS
What technical signals does KBIO LABS (038530) have?
KBIO LABS current technical signals: no active technical signal.
Is KBIO LABS a cup-and-handle pattern?
No. KBIO LABS has no valid cup-and-handle signal right now.
What are KBIO LABS's financials and valuation?
KBIO LABS's income statement, balance sheet and cash flow are free for the most recent 8 years; the full history is on Pro. PER/PBR, dividend yield and sector valuation bands are free.

Like these rules? Backtest them.

Run this signal on this ticker in the free backtest builder — same window, no install.

Backtest this rule ↗

Quantus Signal · live data · not investment advice · Privacy Policy